• Figure 1.

    Algorithm showing treatment scheme for chronic kidney disease (CKD) G1 to G5D

  • Figure 2.

    Algorithm showing treatment scheme for kidney transplant recipients (KTRs)

  • Figure 3.

    Algorithm showing proposed strategy in a kidney transplantation candidate infected with hepatitis C virus (HCV)

  • 1.

    KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl 2018; 8:91165.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Park H, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology 2018; 67:492504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Jadoul M, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019; 95:939947.

  • 4.

    Pol S, et al. Hepatitis C virus and the kidney. Nat Rev Nephrol 2019; 15:7386.

  • 5.

    De Vita S, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843853.

  • 6.

    Towards elimination of viral hepatitis by 2030. Lancet 2016; 388:308.

New Guideline Update: Hepatitis C in Patients with Chronic Kidney Disease

Michel Jadoul Michel Jadoul, MD, is head of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Search for other papers by Michel Jadoul in
Current site
Google Scholar
Restricted access